Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

3.1 Levodopa infusion for Parkinson's disease

Per Odin  1 , Kristina Rosqvist  2
Per Odin  1   2 , K Ray Chaudhuri  3   2 , Sten-Magnus Aquilonious  2 , Ulrika Mundt-Petersen  2
, editors.
In: Where are We? Continuous Dopaminergic Stimulation for Parkinson's Disease [Internet]. Berkshire (UK): Empowering Strategic Performance Ltd; 2023 Jan 1.
Affiliations
Free Books & Documents
Review

3.1 Levodopa infusion for Parkinson's disease

Per Odin et al.
Free Books & Documents
No abstract available

PubMed Disclaimer

References

    1. Fernandez HH, Boyd JT, Fung VSC, et al. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. Mov Disord. 2018;33:928–936. - PubMed
    1. Shoulson I, Glaubiger GA, Chase TN. On-off response: Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology. 1975;25:1144–1148. - PubMed
    1. Nyholm D, Aquilonius SM. Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin Neuropharmacol. 2004;27:245–256. - PubMed
    1. Kurlan R, Rubin AJ, Miller C, et al. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol. 1986;20:262–265. - PubMed
    1. Nyholm D, Jost WH. Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance. Ther Adv Neurol Disord. 2022;15:17562864221108018. - PMC - PubMed

LinkOut - more resources